Sartorius Projects Positive Growth After Strong Nine Months

In the first three quarters of 2025, Sartorius AG reported a 7.5% increase in group sales revenue, reaching 2.611 billion euros, despite currency challenges. The Bioprocess Solutions Division marked nearly a 10% increase due to high-margin consumables sales. Meanwhile, the lab division exhibited gradual recovery.

Underlying EBITDA surged 13% to 774 million euros, elevating the margin by two percentage points to 29.7%. Sartorius anticipates a full-year sales growth of approximately 7%, slightly surpassing previous estimations. The company forecasts its EBITDA margin will slightly exceed 29.5%.

CEO Dr. Michael Grosse emphasized the strength of the biopharmaceutical market, driven by innovation and rising demand for new drugs. Sartorius continues to address these industry needs, though equipment investments remain cautious.